| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Adam P Cribbs | Q86563634 |
| P2093 | author name string | Sumeth M W Perera | |
| P2860 | cites work | Human germline gene modification: a dissent. | Q53548922 |
| Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee | Q64379319 | ||
| Genome engineering using the CRISPR-Cas9 system | Q22122027 | ||
| Don’t edit the human germ line | Q22122315 | ||
| CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes | Q22337358 | ||
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes | Q24625361 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases | Q26799640 | ||
| Gene targeting in mice: a review | Q27001077 | ||
| RNA-programmed genome editing in human cells | Q28044562 | ||
| Therapeutic genome editing: prospects and challenges | Q28087380 | ||
| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV | Q28235281 | ||
| Highly efficient endogenous human gene correction using designed zinc-finger nucleases | Q28243157 | ||
| Genome editing. The new frontier of genome engineering with CRISPR-Cas9 | Q28252298 | ||
| A simple cipher governs DNA recognition by TAL effectors | Q28265506 | ||
| Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients | Q28303521 | ||
| ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering | Q29615505 | ||
| Genetic engineering of human pluripotent cells using TALE nucleases | Q29619830 | ||
| Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins | Q33657682 | ||
| CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences | Q33791286 | ||
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| Toll meets bacterial CpG-DNA. | Q34260232 | ||
| Science communication as political communication | Q34280212 | ||
| CRISPR interference (CRISPRi) for sequence-specific control of gene expression | Q34378409 | ||
| Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century | Q34423288 | ||
| CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus | Q34478938 | ||
| Applications of the CRISPR-Cas9 system in cancer biology | Q34479139 | ||
| High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. | Q34507554 | ||
| Progress and problems with the use of viral vectors for gene therapy | Q35120176 | ||
| Mechanism and regulation of human non-homologous DNA end-joining | Q35542018 | ||
| In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 | Q35820051 | ||
| No time to waste--the ethical challenges created by CRISPR: CRISPR/Cas, being an efficient, simple, and cheap technology to edit the genome of any organism, raises many ethical and regulatory issues beyond the use to manipulate human germ line cells | Q36270836 | ||
| Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. | Q37022952 | ||
| Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. | Q37420333 | ||
| Rational design of inducible CRISPR guide RNAs for de novo assembly of transcriptional programs | Q37682943 | ||
| Genome modification by CRISPR/Cas9. | Q38260231 | ||
| Potential pitfalls of CRISPR/Cas9-mediated genome editing | Q38624926 | ||
| Ethical issues of CRISPR technology and gene editing through the lens of solidarity | Q38740965 | ||
| Editing DNA Methylation in the Mammalian Genome | Q38744151 | ||
| CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. | Q38779072 | ||
| Ethical and regulatory aspects of genome editing. | Q38800296 | ||
| Adenoviral vector DNA for accurate genome editing with engineered nucleases. | Q38963280 | ||
| Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 | ||
| Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. | Q41873090 | ||
| Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. | Q42174678 | ||
| Welcome to the CRISPR zoo. | Q44155748 | ||
| Correction of a pathogenic gene mutation in human embryos | Q45370513 | ||
| A brief account of viral vectors and their promise for gene therapy | Q45863967 | ||
| Gene therapy death prompts review of adenovirus vector | Q45864618 | ||
| CRISPR-Cas9 System: Opportunities and Concerns | Q46217536 | ||
| The Ethics of Human Life Extension: The Second Argument from Evolution | Q46656768 | ||
| Sterilization, segregation and community care: ideology and solutions to the problem of mental deficiency in inter-war Britain | Q48825136 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 | ||
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | Cas9 | Q16965677 |
| bioethics | Q194294 | ||
| regulation of gene expression | Q411391 | ||
| CRISPR | Q412563 | ||
| gene editing | Q65363531 | ||
| biomedical investigative technique | Q66648976 | ||
| CRISPR-Cas systems | Q71149179 | ||
| CRISPR-Cas method | Q17310682 | ||
| P304 | page(s) | 625-634 | |
| P577 | publication date | 2017-12-01 | |
| 2017-12-19 | |||
| P1433 | published in | Yale Journal of Biology and Medicine | Q15709982 |
| P1476 | title | Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction. | |
| P478 | volume | 90 |
| Q64114692 | CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review |
| Q57170220 | Gene editing in the context of an increasingly complex genome |
| Q64039611 | Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases |
| Q57729296 | The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies |
Search more.